2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-110302
    6'-GNTI dihydrochloride 2410327-94-3 98%
    6'-GNTI dihydrochloride, a κ-opioid receptor (KOR) agonist, displays bias toward the activation of G protein-mediated signaling over β-arrestin2 recruitment. 6'-GNTI 6'-GNTI dihydrochloride only activates the Akt pathway in striatal neurons.
    6'-GNTI dihydrochloride
  • HY-110303
    Xanthine amine congener dihydrochloride 1962928-23-9 98%
    Xanthine amine congener dihydrochloride (XAC dihydrochloride) is a potent Adenosine A1 receptor and A2 receptor antagonist with IC50 values of 1.8 and 114 nM, respectively. Xanthine amine congener acts as a convulsant agent in mice model.
    Xanthine amine congener dihydrochloride
  • HY-110304
    NPEC-caged-LY379268 1315379-62-4 98%
    NPEC-caged-LY379268 is a type II mGluR agonist.
    NPEC-caged-LY379268
  • HY-110351
    BGC-20-1531 hydrochloride 1962928-26-2 98%
    BGC 20-1531 (PGN 1531) hydrochloride is a potent and selective prostanoid EP4 receptor antagonist, with a pKb of 7.6. BGC 20-1531 hydrochloride has the potential for the research of migraine headache.
    BGC-20-1531 hydrochloride
  • HY-110366
    WAY-181187 oxalate 1883548-85-3 98%
    WAY-181187 (SAX-187) oxalate is a potent and selective full 5-HT6 receptor agonist with a Ki of 2.2 nM and an EC50 of 6.6 nM. WAY-181187 oxalate mediates 5-HT6 receptor-dependent signal pathways, such as cAMP, Fyn and ERK1/2 kinase, as specific agonist.
    WAY-181187 oxalate
  • HY-11052A
    Trap-101 hydrochloride 1216621-00-9 98%
    Trap-101 hydrochloride is a potent, selective and competitive antagonist of NOP receptors over classical opioid receptors. Trap-101 stimulates GTPγ35S binding to CHOhNOP membranes with pKi values of 8.65, 6.60, 6.14 and <5 for NOP, μ-, κ-, and δ-opioid receptors, respectively. Trap-101 attenuates motor deficits in a rat model of parkinson's disease and can be used for the research of nervous system diseases.
    Trap-101 hydrochloride
  • HY-111000
    BNC-1 96335-59-0 98%
    BNC-1 is an Elk-1 activator that can promote phosphorylation and activation of Elk-1.
    BNC-1
  • HY-111011
    CR 665 acetate 958873-83-1 98%
    CR 665 (JNJ 38488502) acetate is a kappa-opioid agonist that may effectively treat visceral pain by activating receptors on afferent nerves within the gut. CR 665 acetate exhibits peripheral selectivity, differentiating its pharmacokinetic profile from that of non-selective opioids like oxycodone. CR 665 acetate has demonstrated a beneficial effect on visceral pain tolerance thresholds without the delayed analgesic response characteristic of opioids that penetrate the brain. CR 665 acetate is proposed for use in managing postoperative pain due to its pain-relieving properties.
    CR 665 acetate
  • HY-111025
    Ectylurea 95-04-5 98%
    Ectylurea, a N-acylurea, can be used in studies of tension and anxiety symptoms, has no effect on the autonomic nervous system, and has no convulsive, analgesic or antispasmodic activity in animals.
    Ectylurea
  • HY-111038
    Capsiconiate 946572-73-2 98%
    Capsiconiate (Coniferyl (E)-8-methyl-6-nonenoate) is a TRPV1 agonist (EC50= 3.2 μM). Capsiconiate can be used to study TRPV1-mediated diseases such as pain, inflammation, and epilepsy(EC50= 3.2 μM).
    Capsiconiate
  • HY-111051
    JN403 942606-12-4 98%
    JN403 is an orally active and selective α7 nicotinic acetylcholine receptor agonist. JN403 can be used in the study of central nervous system disorders.
    JN403
  • HY-111093
    Protein kinase inhibitor 8 926319-75-7 98%
    Protein kinase inhibitor 8 (Compound CK59) is a calmodulin-dependent protein kinase II (CaMKII) inhibitor. By inhibiting the activity of CaMKII, Protein kinase inhibitor 8 can attenuate the cytotoxicity induced by perfluorooctane sulfonic acid (PFOS) and alleviate the downregulation of GLT-1 expression caused by PFOS, thereby reducing neuronal damage. Protein kinase inhibitor 8 may be useful in research related to neurodegenerative diseases.
    Protein kinase inhibitor 8
  • HY-111124
    Paroxetine-d2 923932-43-8 98%
    Paroxetine-d2 (CTP 347) is a deuterium labeled Paroxetine (HY-122272). Paroxetine is an oral inhibitor that falls under the category of selective serotonin reuptake inhibitors (SSRIs). Paroxetine is also a very weak norepinephrine (NE) reuptake inhibitor, capable of inducing cell apoptosis and having anti-tumor activity. Paroxetine has antidepressant, anti-anxiety, and pain-relieving effects, and it can help improve conditions like obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual anxiety, and chronic headaches.
    Paroxetine-d2
  • HY-111155
    RBI-257 maleate 911378-38-6 98%
    RBI-257 maleate is a potent dopamine D4 receptor antagonist with a Ki value of 0.3 nM.
    RBI-257 maleate
  • HY-111157
    Dezinamide 91077-32-6 98%
    Dezinamide (ADD94057) is an antiepileptic agent. Dezinamide binds to the voltage-sensitive sodium channel.
    Dezinamide
  • HY-111189
    GSK931145 896117-64-9 98%
    GSK931145 is a glycine transporter 1 (GlyT1) inhibitor with anti-epileptic activity. GSK931145 exhibits a low minimum effective dose in the maximum electrical stimulation threshold test, indicating that it has a significant anti-epileptic effect. GSK931145 is also suitable as a positron emission tomography (PET) radioligand for quantifying the availability of glycine transporters in the living brain.
    GSK931145
  • HY-111197
    LY-2300559 889116-06-7 98%
    LY-2300559 is a low-solubility carboxylic acid (pKa = 4.5). LY-2300559 can be used for the research of migraine.
    LY-2300559
  • HY-111218
    TRPV1 antagonist 5 878811-00-8 98%
    TRPV1 antagonist 5 (compound 1) is a potent TRPV1 antagonist.
    TRPV1 antagonist 5
  • HY-111239
    GSK317354A 874119-13-8 98%
    GSK317354A is a ROCK and GRK inhibitor. GSK317354A can be used for heart failure and Parkinson’s disease research.
    GSK317354A
  • HY-111241
    SV 293 873445-73-9 98%
    SV 293 is a selective antagonist with neutral antagonist activity. SV 293 binds to human D2 receptors with 100-fold higher affinity and has lower affinity for human D3 and D4 dopamine receptor subtypes. SV 293 was found to block the effects of the full agonist quinpirole in forskolin-dependent adenylate acylase inhibition assays and electrophysiological assays. SV 293 can be used as a useful pharmacological tool to study the role of dopamine D2-like receptor subtypes in dopamine pathways associated with neurological, neuropsychiatric and movement disorders.
    SV 293
Cat. No. Product Name / Synonyms Application Reactivity